Schlich Ltd +44(0) 1903 717001 info@schlich.co.uk
  • Schlich China
  • Client Portal
Schlich Ltd
  • Our Firm
  • IP Services
    • Patents
    • EPO Oppositions & Appeals
    • UKIPO Proceedings
    • UPC Proceedings
    • Trade Marks
    • Designs
    • IP Strategy
  • Patent Specialities
    • Life Sciences & Biotech
    • Chemical & Pharmaceutical
    • Mechanical, Engineering and Physics
    • Software, Electronics and Communications
  • Insights
  • Inventors’ Zone
  • Contact
Select Page
When it comes to Post Filed Data, the Earlier the Better – A Brief Reminder Following G 2/21

When it comes to Post Filed Data, the Earlier the Better – A Brief Reminder Following G 2/21

by | Apr 29, 2025 | EPO

Specifically, the closest prior art in this case taught that a higher concentration of a particular component of the composition was advantageous. The Patentee attempted to argue that the claimed composition was inventive over the art on the basis that the same...
UniQure’s Haemophilia B gene-therapy patent found valid – and infringed by Pfizer

UniQure’s Haemophilia B gene-therapy patent found valid – and infringed by Pfizer

by David Eyre | Dec 6, 2024 | UK

Haemophilia B   A blot clot is produced following a cascade of reactions after injury. Haemophilia is a disorder of blood clotting whereby one of the factors that contributes to this cascade of reactions is defective. Consequently, for sufferers from this condition...
The Federal Circuit clarifies conflicts arising between Patent Term Adjustment and Obviousness-type Double Patenting

The Federal Circuit clarifies conflicts arising between Patent Term Adjustment and Obviousness-type Double Patenting

by David Eyre | Sep 16, 2024 | US & International

Background  For valuable inventions it is relatively typical for a US patent to be expanded into a family of patent rights. Naturally, the value of patents is further enhanced by extra patent term.  Patents with expiry dates beyond the normal 20 year period can be...
What Satisfies the Palate of the EPO’s Boards of Appeal? Fish Oil and Fruit Juice, Apparently…

What Satisfies the Palate of the EPO’s Boards of Appeal? Fish Oil and Fruit Juice, Apparently…

by Sean Hutchinson | Aug 30, 2024 | EPO

Background European patent no. EP 2 991 507 B1 was granted with claims directed to a mixture containing fish oil and fruit juice for use in the treatment of cancer. At opposition, the patent was found to lack novelty and the amendments proposed by the patent...
Boards of Appeal Introduce New Broad Interpretation of “Substance or Composition” in the Context of Second Medical Use Claims

Boards of Appeal Introduce New Broad Interpretation of “Substance or Composition” in the Context of Second Medical Use Claims

by Chloe Sullivan | Aug 29, 2024 | EPO, Uncategorised

Background Due to methods of treatment of the human or animal body being excluded from patentability in Europe, applicants are required to claim substances or compositions for use in a method of treatment instead. Thus, there is a need for the term “substances or...
« Older Entries
Next Entries »

Recent Posts

  • By Touatis! “Obelix®” Has A Reputation
  • Schlich recognised in IAM Patent 1000 rankings for 2026
  • First UPC Referral to the CJEU: Just How Long is the Long-Arm Jurisdiction of the UPC?
  • Sequence Identity Claims After T 0137/24: How Broad Is Too Broad?
  • Schlich’s 2026 Reception Aboard the Golden Hinde

Recent Comments

    CIPA
    IPReg
    CITMA
    • Instagram

    Services

    • Patents
    • EPO Oppositions & Appeals
    • UKIPO Proceedings
    • UPC Proceedings
    • Trade Marks
    • Designs
    • IP Strategy

    About

    • Our Firm
    • Careers
    • Our People
    • Policies

    Contact

    • Contact
    • Inventors Zone
    © 2026 Schlich, All rights reserved | Built by Molokini
    European Patent and Trade Mark Attorneys. Schlich Ltd is a UK limited company, registration no. 05238489, address: 9 St Catherine's Road, Littlehampton, West Sussex, BN17 5HS.